IGF-I Double Nickase Plasmid (h): sc-400271-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- IGF-I Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- IGF-I Double Nickase Plasmid (h) and IGF-I Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting IGF1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: IGF-I Antibody (W18): sc-74116
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IGF-I Double Nickase Plasmid (h) | sc-400271-NIC | 20 µg | $410.00 | |||
IGF-I Double Nickase Plasmid (h2) | sc-400271-NIC-2 | 20 µg | $410.00 |
IGF1 encodes insulin-like growth factor I (IGF-I), a secreted peptide hormone that regulates somatic growth, cell survival, and metabolic homeostasis in human tissues. IGF-I signals primarily through IGF1R to activate PI3K–AKT–mTOR and RAS–RAF–MEK–ERK pathways, influencing protein synthesis, cell-cycle progression, and anti-apoptotic programs. Autocrine and paracrine IGF axis activity intersects with insulin signaling and is modulated by IGF binding proteins, shaping bioavailability and receptor engagement. Dysregulated IGF1 expression or signaling is implicated in growth disorders and contributes to research models of oncogenic signaling, metabolic disease biology, and tissue regeneration.
IGF-I Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the IGF1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within IGF1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt IGF1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of IGF1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.